Cancer Cell-Targeted siRNA Delivery by Folate-Conjugated Gold-siRNA-PEG/PEI Nanop

描述(由申请人提供)： 在美国，癌症是导致所有人死亡的第二大疾病，仅次于心脏病。虽然siRNA对基因表达的下调已被证明是有效的和靶基因特异性的，但目前还没有一种治疗上可以接受的方法，只高效地靶向癌细胞，而不影响正常细胞。在拟议的研究中，我们将制备、表征和测试一种新型的叶酸偶联的多组分金-siRNA纳米复合体系统，该系统允许通过叶酸受体辅助的内吞作用将纳米复合体输送到癌细胞。金-siRNA纳米复合体将由预制的金纳米颗粒逐步组装而成，并通过化学和酶法合成硫代RNA和硫代RNA-聚乙二醇叶酸偶联物。将通过核磁共振、高效液相、凝胶电泳、动态光散射、Zeta电位和透射电子显微镜进行广泛的表征。使用不同的癌细胞系(A549、KB、HeLa和SKOV3)，我们将分析细胞内递送效率、特定基因敲除以及细胞功能研究，包括抑制细胞生长和细胞死亡。预计拟议的研究将开发一种基于主动靶向金纳米颗粒的新的siRNA递送系统。有效下调必要基因[Survivin和CASP8AP2(caspase 8相关蛋白2，一种凋亡因子)]将导致抑制癌细胞生长和癌细胞死亡。 公共卫生相关性： 该项目将开发一种新型的叶酸偶联Au-siRNA纳米复合体系统。Au-siRNA纳米复合体将实现对癌细胞的特异性siRNA传递和基因表达的有效下调。必要基因的敲除会导致癌细胞生长抑制和癌细胞死亡。这项研究可能会导致用于癌症治疗的治疗性siRNA递送系统的开发。

DESCRIPTION (provided by applicant): Cancer is the second leading course for all deaths in the United States, surpassed only slightly by heart disease. Although down-regulation of gene expression by siRNA has been shown to be both potent and target gene-specific, there is currently no therapeutically acceptable method for siRNA delivery that targets only cancer cells with high efficiency without affecting normal cells. In the proposed research, we will prepare, characterize, and test a novel folate-conjugated multicomponent gold-siRNA nanoplex system, which permits cancer cell-specific delivery of the nanoplexes through folate receptor-assisted endocytosis. The gold-siRNA nanoplex will be assembled stepwise from pre-made gold nanoparticles and chemically and enzymatically synthesized thioRNA and thioRNA-PEG-folate conjugates. Extensive characterization will be performed by NMR, HPLC, gel electrophoresis, dynamic light scattering, zeta potential, and transmission electron microscopy. Using different cancer cell lines (A549, KB, HeLa, and SKOV3), we will analyze intracellular delivery efficiency, specific gene knockdown, and cellular function studies including inhibition of cell growth and cell death. It is expected that the proposed research will develop a new siRNA delivery system based on actively targeted gold nanoparticles. Effective down-regulation of essential genes [survivin and CASP8AP2 (caspase 8 associated protein 2, an apoptosis factor)] will lead to inhibition of cancer cell growth and cancer cell death. PUBLIC HEALTH RELEVANCE: The proposed project will develop a novel folate-conjugated Au-siRNA nanoplex system. Specific siRNA delivery to cancer cells and efficient down-regulation of gene expression will be achieved by the Au-siRNA nanoplex. Knockdown of essential genes will cause cancer cell growth inhibition and cancer cell death. The research may lead to the development of therapeutic siRNA delivery systems for cancer treatment.